Cancer stem cells in gliomas: evolving concepts and therapeutic implications

Purpose of review Cancer stem cells (CSCs) have been implicated in the hierarchical heterogeneity and treatment resistance of hematologic and solid tumor malignancies, including gliomas, for several decades now but their therapeutic targeting has not been fully realized. Recent studies have uncovered deeper layers of CSC complexity, related to developmental origins, plasticity, cellular states, and interface with the microenvironment. Recent findings Sequencing and in-vivo lineage-tracing studies in mouse and patient-derived models show evidence of stem and progenitor origin of glioma, at the same time that genomic studies show a relatedness of glioma CSCs with radial glia. The spate of single-cell sequencing analyses demonstrates the diversity of transcriptional cellular states, which are susceptible to transitions, indicating the plasticity of glioma CSCs. The evolution of glioma CSCs and their interactions with niche cells play important roles in CSC treatment resistance and immune evasion, with epigenetic modulation as one of the emerging mechanisms. Summary To harness the potential of CSCs for clinical application, there is urgent need to investigate their complex nature and myriad interactions, to better understand the contribution of these self-renewing, stem-like cancer cells in the pathogenesis and therapy resistance of malignant brain tumors.

[1]  S. Beck,et al.  Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion , 2021, Cell.

[2]  Gary D Bader,et al.  PRMT5 inhibition disrupts splicing and stemness in glioblastoma , 2021, Nature Communications.

[3]  C. Brennan,et al.  PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. , 2021, Molecular cell.

[4]  S. Bicciato,et al.  Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in Glioblastoma , 2020, Nature Cancer.

[5]  C. Brennan,et al.  Cell Lineage-Based Stratification for Glioblastoma. , 2020, Cancer cell.

[6]  I. Tirosh,et al.  The Glioma Stem Cell Model in the Era of Single-Cell Genomics. , 2020, Cancer cell.

[7]  J. Rich,et al.  Glioblastoma Stem Cells: Driving Resilience through Chaos. , 2020, Trends in cancer.

[8]  A. Iwasaki,et al.  VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours , 2020, Nature.

[9]  Madeline G. Andrews,et al.  Outer Radial Glia-like Cancer Stem Cells Contribute to Heterogeneity of Glioblastoma. , 2020, Cell stem cell.

[10]  D. Pe’er,et al.  Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma , 2019, Nature Medicine.

[11]  N. Takebe,et al.  Targeting signalling pathways and the immune microenvironment of cancer stem cells — a clinical update , 2019, Nature Reviews Clinical Oncology.

[12]  Mariella G. Filbin,et al.  An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma , 2019, Cell.

[13]  J. Rich,et al.  Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer , 2019, Genes & development.

[14]  N. Batada,et al.  Wnt and Notch signaling govern self-renewal and differentiation in a subset of human glioblastoma stem cells , 2019, Genes & development.

[15]  P. Gutin,et al.  Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma , 2019, Nature.

[16]  D. Burns,et al.  Cell-of-origin susceptibility to glioblastoma formation declines with neural lineage restriction , 2019, Nature Neuroscience.

[17]  A. Álvarez-Buylla,et al.  Neural stem cells: origin, heterogeneity and regulation in the adult mammalian brain , 2019, Development.

[18]  P. Wen,et al.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma , 2018, Nature Medicine.

[19]  Ji-Yong Um,et al.  Human glioblastoma arises from subventricular zone cells with low-level driver mutations , 2018, Nature.

[20]  Tracy T Batchelor,et al.  Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq , 2018, Science.

[21]  Mauro J. Muraro,et al.  Troy+ brain stem cells cycle through quiescence and regulate their number by sensing niche occupancy , 2018, Proceedings of the National Academy of Sciences.

[22]  H. Clevers,et al.  Cancer stem cells revisited , 2017, Nature Medicine.

[23]  Richard A. Moore,et al.  Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy , 2017, Nature.

[24]  Edward F. Chang,et al.  Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. , 2017, Cancer cell.

[25]  Shawn M. Gillespie,et al.  Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. , 2017, Cell stem cell.

[26]  Mariella G. Filbin,et al.  Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq , 2017, Science.

[27]  Xiuli Wang,et al.  Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. , 2016, The New England journal of medicine.

[28]  Mariella G. Filbin,et al.  Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma , 2016, Nature.

[29]  D. Merico,et al.  Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Euiseok J. Kim,et al.  Adult Lineage-Restricted CNS Progenitors Specify Distinct Glioblastoma Subtypes. , 2015, Cancer cell.

[31]  R. Verhaak,et al.  Transformation of quiescent adult oligodendrocyte precursor cells into malignant glioma through a multistep reactivation process , 2014, Proceedings of the National Academy of Sciences.

[32]  M. Jinushi.  Role of cancer stem cell-associated inflammation in creating pro-inflammatory tumorigenic microenvironments , 2014, Oncoimmunology.

[33]  Simon Kasif,et al.  Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells , 2014, Cell.

[34]  A. Krešo,et al.  Evolution of the cancer stem cell model. , 2014, Cell stem cell.

[35]  L. Deangelis,et al.  Glioblastoma and other malignant gliomas: a clinical review. , 2013, JAMA.

[36]  Se Hoon Kim,et al.  Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. , 2013, Cancer cell.

[37]  R. McLendon,et al.  Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth , 2013, Cell.

[38]  S. Forman,et al.  Stem-like Tumor-Initiating Cells Isolated from IL13Rα2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine–Redirected T Cells , 2012, Clinical Cancer Research.

[39]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[40]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[41]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[42]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[43]  下川 真理子.  Visualization and targeting of LGR5⁺ human colon cancer stem cells(審査報告) , 2017 .

[44]  Tzong-Shiue Yu,et al.  A restricted cell population propagates glioblastoma growth after chemotherapy , 2012 .

[45]  H. Armah.  Malignant Astrocytomas Originate from Neural Stem/Progenitor Cells in a Somatic Tumor Suppressor Mouse Model , 2010 .